Neurophet, an artificial intelligence (AI) company specializing in diagnosis and treatment of brain diseases, said on the 25th that it will carry out joint research cooperation with the Florey Institute of Neuroscience and Mental Health in Australia on the brain nerve degeneration imaging analysis software "Neurophet AQUA."
The joint study aims to assess the usefulness of blood-based biomarkers and Neurophet AQUA for diagnosing and managing Alzheimer's disease in real clinical settings. The two sides plan to accelerate research cooperation on Enhanced Dementia Diagnosis using Neurophet AQUA.
The Florey Institute, located in Melbourne, Australia, is the Southern Hemisphere's largest brain research institute, with more than about 500 researchers and support staff. It primarily studies depression, schizophrenia, bipolar disorder (manic-depressive illness), and neurodegenerative diseases that affect cognitive function.
Peter van Wijngaarden, director overseeing the Florey Institute, said, "Through cooperation with Neurophet, we will accelerate future research into advanced dementia diagnosis," adding, "We are very pleased to announce this research collaboration."
Bin Jun-gil, co-CEO of Neurophet, said, "Through this collaboration, we plan to advance global dementia diagnosis using Neurophet's AI-based brain imaging analysis solution," adding, "We will do our best to demonstrate the clinical validity of biomarkers for the early diagnosis of Alzheimer's disease."